NextCure is a privately-held biopharmaceutical company focused on discovering and developing first-in-class immunomedicines for cancer and other diseases. It uses a proprietary FIND-IO™ discovery platform to identify novel cell-surface molecular interactions that drive immune responses in the tumor microenvironment and to build a pipeline of immunomedicines. The company’s initial focus is bringing treatments to patients who do not respond to current cancer therapies, with two lead drug candidates including NC318. NC318 targets a novel immunomodulatory target on a restricted set of myeloid cells and certain tumor types; preclinical studies show NC318 blocks suppressive myeloid effects and has potential across multiple cancer types. NextCure plans to advance clinical development of its lead candidates, continue preclinical development of additional immunomedicine candidates, and execute on collaborations such as its discovery and development partnership with Eli Lilly. The company is based in Beltsville, Maryland. NextCure is a biopharmaceutical company focused on the discovery and development of new immuno-oncology products. The company leverages proprietary platforms and know-how to identify novel and biologically relevant targets and develop immuno-oncology–based drugs. NextCure was founded in 2015 by Michael Richman and Lieping Chen; Richman serves as President and Chief Executive Officer. The company completed a $67M Series A financing. Investors in the round include Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors, Pfizer, Sofinnova Ventures and Alexandria Venture Investments. In conjunction with the funding, David Kabakoff, Ph.D., executive partner of Sofinnova Ventures, will join as Chairman, and three former Amplimmune executives joined the NextCure management team in senior research, development/manufacturing, and translational research roles.

Total raised

$160M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2018